Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!

Br J Haematol. 2021 May;193(4):697-698. doi: 10.1111/bjh.17433. Epub 2021 Apr 14.
No abstract available

Publication types

  • Comment

MeSH terms

  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Rituximab

Substances

  • Rituximab